Photopheresis, also called extracorporeal photopheresis, is a form of apheresis and photodynamic therapy in which blood is separated to isolate the buffy coat of white cells and platelets, chemically treated with the light-sensitizing compound 8-methoxypsoralen, exposed to ultraviolet A light, and then returned to the patient; the treated cells appear to induce a cytotoxic effect on T-cell formation once returned. Introduced in a 1987 New England Journal of Medicine publication, it is now a standard United States Food and Drug Administration therapy for cutaneous T-cell lymphoma, and evidence, though largely observational, suggests it may also help treat graft-versus-host disease and epidermolysis bullosa acquisita when other treatments have failed.
Facts
Origin YearSourced to the subject's own account Photopheresis
Filter Results3 entries
FAQs
How was photopheresis first introduced?
A 1987 New England Journal of Medicine publication.
Photopheresis was introduced in a 1987 New England Journal of Medicine publication describing treatment involving 8-methoxypsoralen. It is now a standard United States Food and Drug Administration therapy for cutaneous T-cell lymphoma.
Connections
Associated With
Photopheresis is a blood treatment procedure within hematology.
Treats
Source Photopheresis (Wikipedia)
Source Photopheresis (Wikipedia)
Source Photopheresis (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
2. Photopheresis (Wikipedia)
WikipediaLead section, 1987 NEJM sentence
A 1987 New England Journal of Medicine publication introduced photopheresis involving 8-methoxypsoralen.
https://en.wikipedia.org/wiki/Photopheresis, lead section
In medicine, photopheresis (aka extracorporeal photopheresis or ECP) is a form of apheresis and photodynamic therapy in which blood is subject to apheresis to separate buffy coat (WBC + platelets) from whole blood, chemically treated with 8-methoxypsoralen (instilled into a collection bag or given per os in advance), exposed to ultraviolet light (UVA), and then returned to the patient.
Treats: Lymphoma, Lead: treats Lymphoma
A 1987 New England Journal of Medicine publication introduced photopheresis involving 8-methoxypsoralen., now standard U.S. Food and Drug Administration (FDA) therapy for cutaneous T-cell lymphoma.
Treats: Graft-Versus-Host Disease, Lead: treats Graft-Versus-Host Disease
Evidence suggests that this treatment might help treat graft-versus-host disease, though this evidence is largely observational; controlled trials are needed to support this use.
Treats: Ulcerative Colitis, Lead: treats Ulcerative Colitis
Photopheresis is also an experimental treatment for patients with cardiac, pulmonary and renal allograft rejection, graft-versus-host disease, autoimmune diseases, nephrogenic systemic fibrosis and ulcerative colitis.
In Group: Apheresis and Plasma Exchange, Introduction, sentence 1
In medicine, photopheresis (aka extracorporeal photopheresis or ECP) is a form of apheresis and photodynamic therapy in which blood is subject to apheresis to separate buffy coat (WBC + platelets) from whole blood, chemically treated with 8-methoxypsoralen (instilled into a collection bag or given per os in advance), exposed to ultraviolet light (UVA), and then returned to the patient.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.